Comparative Pharmacology
Head-to-head clinical analysis: PENBRITIN S versus PROBAMPACIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PENBRITIN S versus PROBAMPACIN.
PENBRITIN-S vs PROBAMPACIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Penicillinase-sensitive penicillin; inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting transpeptidase activity, and activating autolytic enzymes.
PROBAMPACIN is a synthetic aminoglycoside antibiotic that inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, causing misreading of mRNA and preventing translocation of peptidyl-tRNA from the A-site to the P-site.
250-500 mg orally every 6 hours or 500 mg-1 g intramuscularly/intravenously every 4-6 hours for moderate to severe infections.
100 mg IV every 12 hours over 30 minutes.
None Documented
None Documented
0.5-1 hour; prolonged in renal impairment (up to 7-10 hours in anuria).
4.5 hours (prolonged to 12-18 hours in severe renal impairment)
Renal: 75-90% unchanged via glomerular filtration and tubular secretion; biliary/fecal: ~10%.
Renal: 70% unchanged; biliary/fecal: 20% as metabolites; 10% other
Category C
Category C
Penicillin Antibiotic
Penicillin Antibiotic